AccurKardia Raises $2.7M for Remote Cardiac Care Expansion
AccurKardia, a New York-based medical AI software company, has secured $2.7 million in a seed round. The funding, led by the Popular Impact Fund and joined by Dreamit Ventures and FHL Capital, will support the company's mission to expand access to remote jobs in cardiac care using its high-quality ECG interpretation software.
AccurKardia aims to bring its innovative technology to market, as announced by CEO Juan C. Jiménez. The company has been utilising Mayo Clinic's resources since March 2023 to fast-track its research and development. This collaboration, facilitated by AccurKardia's selection for Cohort 3 of the Mayo Clinic Platform Accelerate program, has provided access to valuable datasets and mentorship.
The seed round funding will enable AccurKardia to collaborate with leading providers, further enhancing its remote jobs in cardiac care offerings. The company's ECG interpretation software is designed to improve patient outcomes by enabling timely and accurate diagnosis from anywhere.
AccurKardia's $2.7 million seed round, backed by the Popular Impact Fund, Dreamit Ventures, and FHL Capital, will fuel the company's expansion into remote jobs in cardiac care. With Mayo Clinic's support, AccurKardia is poised to revolutionise cardiac care delivery, making it more accessible and efficient.
